<DOC>
	<DOCNO>NCT00210457</DOCNO>
	<brief_summary>To evaluate long-term efficacy safety repeat injection lanreotide Autogel give dos titrate effect acromegalic patient previously treat somatostatin analogue .</brief_summary>
	<brief_title>Efficacy Safety Lanreotide Autogel ( 60 , 90 120 mg ) Acromegalic Patients</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Patient documentation support diagnosis active acromegaly one follow definition : patient receive neither somatostatin analogue dopaminergic agonist within previous 12 week IGF1 level least 1.3 time upper limit ageadjusted normal range , patient treat somatostatin analogue ( lanreotide autogel ) dopaminergic agonist attend first visit end washout period IGF1 level least 1.3 time upper limit ageadjusted normal range . Patient pituitary surgery within previous 3 month Patient receive radiotherapy acromegaly disease within previous 36 month Patient predict require pituitary surgery ( adenomectomy ) receive radiotherapy study period Patient receive lanreotide autogel time study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
</DOC>